The latest biotech news

News and Trends 11 Jul 2023

NodThera first to show reduction in neuroinflammation with inflammasome inhibitor

NodThera has announced positive, initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and…

July 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jul 2023

NK:IO awarded £1.6M grant to develop NK cell therapy

NK:IO, a U.K. company working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, has been awarded £1.6 million ($2.1…

July 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jul 2023

Inhaled mRNA medicines redefine respiratory disease treatment

By Carsten Rudolph, co-founder and CEO of Ethris Advancements in mRNA technology have led to the development of inhaled mRNA medicines, which hold tremendous potential for revolutionizing the treatment of…

July 11, 2023 - 3 minutesmins - By External Contributor

News and Trends 10 Jul 2023

Existing cancer drug could be repurposed to fight certain aggressive cancers

A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has found that an existing cancer drug could be repurposed to target a subset of cancers that currently…

July 10, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology

CytoMed Therapeutics Limited, a Singapore-based biopharma company focused on novel donor cell-based immunotherapies for the treatment of various cancers, has announced that its CAR-gamma delta T cell (CAR-γδ T cell)…

July 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

TolerogenixX expands trial and closes €12M financing

TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in…

July 7, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

FDA approves Alzheimer’s treatment

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI…

July 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 7 Jul 2023

Swedish researchers look to peptides to destroy viruses

A new study from Sweden shows how a type of peptide from a lactic acid bacterium destroys viruses, including coronavirus. The findings have resulted in a Swedish patent, with an…

July 7, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

LIfT produces neutrophil-based cell therapy from iPSCs

LIfT BioSciences has announced successful proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). The proof-of-concept using iN-LIfT, the company’s second-generation platform, which is derived…

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

Positive data from Sensorion hearing loss study

Sensorion, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has reported further analysis from its Proof of Concept…

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

AstraZeneca non-small cell lung cancer drug meets primary endpoint

Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel,…

July 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jul 2023

£100M LifeArc program aims to help people living with rare diseases

LifeArc, a self-funded, non-profit medical research organization and charity, is launching a new program to invest more than £100 million ($127.2 million) by 2030 to deliver new breakthroughs to improve…

July 6, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 5 Jul 2023

Narcolepsy drug gets Chinese approval

RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, has announced that the Chinese National Medical Products Administration (NMPA) has approved pitolisant (Wakix)…

July 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Innovent Biologics, Inc. and IASO Biotechnology have announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first…

July 4, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Camena Bioscience raises $10M for DNA synthesis platform

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, has closed a $10m Series A financing round, led by Mercia. The new funding will be…

July 4, 2023 - 2 minutesmins - By Jim Cornall

Cristina Müller heads the Nuclide Chemistry research group at the Paul Scherrer Institute.

News and Trends 4 Jul 2023

New drug helps prostate cancer patients

Researchers at the Paul Scherrer Institute (PSI) in Switzerland have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now…

July 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Jul 2023

Exeliom Biosciences closes €24M financing for lead candidate

Exeliom Biosciences has completed a €24 million ($26 million) Series A to progress the clinical development of its therapeutic pipeline. This includes several clinical trials of EXL01, a novel immunotherapy…

July 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jul 2023

New osteoarthritis treatment for horses could work for humans

For the first time, an intervention that seems to slow down osteoarthritis (OA) progression has been presented. In a clinical study from the Swedish University of Agricultural Sciences and the…

July 3, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 30 Jun 2023

Scientists design new enzyme using Antarctic bacteria and computer calculations

For the first time, researchers have succeeded in predicting how to change the optimum temperature of an enzyme using large computer calculations. A cold-adapted enzyme from an Antarctic bacterium was…

June 30, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 30 Jun 2023

FDA approves BioMarin gene therapy for hemophilia A

BioMarin Pharmaceutical Inc. has announced that the United States Food and Drug Administration (FDA) has approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A…

June 30, 2023 - 5 minutesmins - By Jim Cornall

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering

Outsourcing in life science R&D today

Power your event with partnering to deliver attendee ROI.

Looking to expand your network?

Subscribe to our newsletter to get the latest biotech news!